A detailed history of Bayesian Capital Management, LP transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Bayesian Capital Management, LP holds 27,080 shares of PCRX stock, worth $450,611. This represents 0.05% of its overall portfolio holdings.

Number of Shares
27,080
Holding current value
$450,611
% of portfolio
0.05%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$11.7 - $28.46 $316,836 - $770,696
27,080 New
27,080 $407,000
Q2 2019

Aug 13, 2019

SELL
$36.57 - $47.97 $365,700 - $479,700
-10,000 Closed
0 $0
Q1 2019

May 14, 2019

BUY
$36.47 - $42.17 $364,700 - $421,700
10,000 New
10,000 $381,000
Q1 2018

May 15, 2018

SELL
$29.98 - $46.35 $441,005 - $681,808
-14,710 Closed
0 $0
Q4 2017

Feb 12, 2018

BUY
$31.85 - $46.95 $468,513 - $690,634
14,710
14,710 $672,000

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $763M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Bayesian Capital Management, LP Portfolio

Follow Bayesian Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bayesian Capital Management, LP with notifications on news.